A Phase 3 interventional study of Roxadustat and Placebo in CKD Anemia, sponsored by FibroGen. Completed at 145 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.
Sponsored by FibroGen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.
Among the 43 studies testing roxadustat in Anemia, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 25 in phase 3, and was the 9th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:
Kyntra Bio
Ages 18+
Tianjin Medical University General Hospital
Ages 18–80
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 2006; this study’s year is marked. 2 started in 2012.
This study's enrollment of 922 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 154 across the 43 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
21 studies in Anemia by Kyntra Bio: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 21 studies in Anemia by Kyntra Bio, this one is the 2nd largest by enrollment, is one of 2 that started in 2012, is one of 11 in phase 3, and was the 8th registered.
Kyntra Bio’s Anemia studies by the year they started, since 2006.
1 of the studies testing roxadustat in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing roxadustat in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 21 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.
There is a screening period of up to 6 weeks, a variable treatment period for individual participants. In order to complete the treatment period simultaneously for all study participants, the minimum treatment duration may be less than 52 weeks, with a maximum treatment duration of up to 3 years after the last participant is randomized, and a post-treatment follow-up period of 4 weeks. Participants who prematurely discontinued from treatment will be expected to complete the Early Termination (ET) and End of Study (EOS) visits. Such participants will be considered non-completers, but they will be expected to participate in long-term follow-up (LTFU) for cardiovascular events (CV) of interest, vital status, and hospitalizations until overall study closure unless the participant withdrew consent for this LTFU data collection. Participants were randomized in a 2:1 ratio to receive either roxadustat or placebo in a double-blind manner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
Drug: Roxadustat
Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing \<70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.
Drug: Placebo
Oral tablets
Also known as: FG-4592, ASP1517, AZD9941
Oral tablets
United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy
The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.
Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52
Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy
The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell \[RBC\] transfusion, erythropoiesis-stimulating agent \[ESA\], or intravenous \[IV\] iron) are reported. A Hb response is defined, using central laboratory values, as the following: * Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb \>8 g/dL, or * An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL
Time frame: Baseline up to Week 24
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.
Time frame: Baseline (Day 1, Week 0), Weeks 28 to 36
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)
Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.
Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52
Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.
Time frame: Weeks 28 to 36
Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.
Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28
Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)
Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.
Time frame: Baseline, Month 12
Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment
Participants with any use of blood/RBC transfusion were reported.
Time frame: Baseline up to Week 52
Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment
Rescue therapy included any use of RBC transfusion, ESA, or IV iron.
Time frame: Baseline (Day 1, Week 0) up to Week 24 and up to Week 52
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.
Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28
Number (%) of Participants Who Experienced Exacerbation of Hypertension
Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.
Time frame: Baseline up to Week 52
Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
Baseline MAP was defined as the last MAP value prior to the first dose of study drug.
Time frame: Baseline, Weeks 20 to 28
| Milestone | Roxadustat | Placebo |
|---|---|---|
| Started | 616 | 306 |
| Safety population | 611 | 305 |
| Full analysis set (fas) | 608 | 305 |
| Completed | 349 | 98 |
| Not completed | 267 | 208 |
| Withdrew: Adverse event | 47 | 19 |
| Withdrew: Death | 38 | 11 |
| Withdrew: Lack of efficacy (including erythropoiesis-stimulating agent rescue) | 2 | 43 |
| Withdrew: Lost to follow-up | 28 | 7 |
| Withdrew: Physician decision | 16 | 17 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Study/site terminated by sponsor | 4 | 1 |
| Withdrew: Withdrawal by subject | 83 | 89 |
| Withdrew: Kidney transplant | 8 | 4 |
| Withdrew: Dialysis | 22 | 8 |
| Withdrew: Other than specified | 13 | 4 |
The change in Hb from baseline to the average level during the evaluation period (defined as Week 28 until Week 52) is reported. Hb values under the influence of a rescue therapy were not censored. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.
| g/dL | Roxadustat | Placebo |
|---|---|---|
| Baseline | 9.10 ± 0.75 | 9.09 ± 0.69 |
| Change at Weeks 28 to 52 | 2.00 ± 0.952 | 0.16 ± 0.895 |
The number of participants who achieved a Hb response at 2 consecutive visits at least 5 days apart during the first 24 weeks of treatment, without rescue therapy (that is, red blood cell \[RBC\] transfusion, erythropoiesis-stimulating agent \[ESA\], or intravenous \[IV\] iron) are reported. A Hb response is defined, using central laboratory values, as the following: * Hb ≥11 g/dL and Hb increase from baseline by ≥1 g/dL in participants with baseline Hb \>8 g/dL, or * An increase in Hb by ≥2 g/dL in participants with baseline Hb ≤8.0 g/dL
| Participants | Roxadustat | Placebo |
|---|---|---|
| Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy | 523 | 20 |
For Ex-US submission only: Hb values under the influence of a rescue therapy were censored by mixed effect model of repeated measures (MMRM) for up to 6 weeks. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study drug.
| g/dL | Roxadustat | Placebo |
|---|---|---|
| Baseline | 9.09 ± 0.749 | 9.09 ± 0.694 |
| Change at Weeks 28 to 36 | 2.02 ± 1.067 | 0.20 ± 0.994 |
Hb values under the influence of a rescue therapy were not censored in the analysis. The intermittent missing hemoglobin data were imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group. Baseline Hb was defined as the mean of up to 4 last central laboratory values prior to the first dose of study treatment.
| g/dL | Roxadustat | Placebo |
|---|---|---|
| Baseline | 9.10 ± 0.750 | 8.99 ± 0.668 |
| Change at Weeks 28 to 52 | 2.02 ± 0.933 | 0.18 ± 0.946 |
Hb values under the influence of a rescue therapy were censored by Cochran-Mantel-Haenszel Test for up to 6 weeks. Responder was defined as: Hb ≥10.0 g/dL, which was based on central laboratory values.
| Participants | Roxadustat | Placebo |
|---|---|---|
| Number (%) of Participants With Hb ≥10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy | 467 | 56 |
Baseline LDL cholesterol was defined as the last LDL cholesterol value prior to the first dose of study drug.
| mg/dL | Roxadustat | Placebo |
|---|---|---|
| Baseline | 97.74 ± 39.09 | 96.39 ± 40.06 |
| Change at Weeks 12 to 28 | -18.48 ± 29.60 | 0.22 ± 29.37 |
Progression of chronic kidney disease was measured by rate of change in eGFR over time adjusted by baseline eGFR, with censoring for chronic dialysis or kidney transplant, using random slope and intercept model. Least Square Mean of change from baseline at 1 year was derived based on a random slopes and intercepts model using all available eGFR values (1 baseline and all post-treatment values up to end of treatment period + 7 days or start of dialysis) adjusted on treatment, baseline Hb, baseline eGFR, geographical region, cardiovascular events history at Baseline (yes vs. no), time (continuous value), the interaction terms of baseline eGFR by time, baseline Hb by time, and treatment by time as fixed effects, with random effects of intercept and linear slope of time. All assessments collected after the start of stable dialysis or kidney transplant were excluded from the analysis.
| ml/min/1.73 m^2 | Roxadustat | Placebo |
|---|---|---|
| Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data) | -2.89 ± 0.363 | -3.10 ± 0.388 |
Participants with any use of blood/RBC transfusion were reported.
| Participants | Roxadustat | Placebo |
|---|---|---|
| Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment | 34 | 47 |
Rescue therapy included any use of RBC transfusion, ESA, or IV iron.
| Participants | Roxadustat | Placebo |
|---|---|---|
| 24 Weeks | 29 | 61 |
| 52 Weeks | 54 | 88 |
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). A higher score indicates a general improvement of life quality or well-being. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.
| scores on a scale | Roxadustat | Placebo |
|---|---|---|
| Physical functioning subscore: Baseline | 41.16 ± 10.121 | 41.35 ± 10.070 |
| Physical functioning subscore: Change at Weeks 12 to 28 | 0.33 ± 7.302 | -0.27 ± 7.363 |
| Vitality subscore: Baseline | 48.19 ± 10.146 | 47.62 ± 9.774 |
| Vitality subscore: Change at Weeks 12 to 28 | 1.90 ± 8.705 | 1.02 ± 8.334 |
Exacerbation of hypertension was defined as an increase from baseline of ≥20 millimeter of mercury (mmHg) in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥110 mmHg.
| Participants | Roxadustat | Placebo |
|---|---|---|
| Number (%) of Participants Who Experienced Exacerbation of Hypertension | 140 | 48 |
Baseline MAP was defined as the last MAP value prior to the first dose of study drug.
| mmHg | Roxadustat | Placebo |
|---|---|---|
| Baseline | 92.16 ± 8.538 | 91.53 ± 8.077 |
| Change at Weeks 20 to 28 | 0.02 ± 8.648 | -0.12 ± 7.653 |
Collected over Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 234.9 weeks for roxadustat and 208.1 weeks for placebo).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat | 38/611 (6.2%) | 321/611 (52.5%) | 468/611 (76.6%) |
| Placebo | 11/305 (3.6%) | 120/305 (39.3%) | 216/305 (70.8%) |
| Event | Roxadustat | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 41/611 | 6/305 |
| End stage renal diseaseRenal and urinary disorders | 34/611 | 10/305 |
| PneumoniaInfections and infestations | 29/611 | 12/305 |
| Chronic kidney diseaseRenal and urinary disorders | 27/611 | 9/305 |
| Cardiac failure congestiveCardiac disorders | 23/611 | 5/305 |
| HyperkalemiaMetabolism and nutrition disorders | 19/611 | 4/305 |
| Urinary tract infectionInfections and infestations | 18/611 | 8/305 |
| AnemiaBlood and lymphatic system disorders | 5/611 | 8/305 |
| HyponatremiaMetabolism and nutrition disorders | 15/611 | 3/305 |
| PeritonitisInfections and infestations | 13/611 | 1/305 |
| Event | Roxadustat | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 103/611 | 34/305 |
| HyperkalemiaMetabolism and nutrition disorders | 98/611 | 38/305 |
| Viral upper respiratory tract infectionInfections and infestations | 97/611 | 40/305 |
| Upper respiratory tract infectionInfections and infestations | 78/611 | 48/305 |
| HypertensionVascular disorders | 93/611 | 26/305 |
| Oedema peripheralGeneral disorders | 89/611 | 28/305 |
| NauseaGastrointestinal disorders | 85/611 | 29/305 |
| AnemiaBlood and lymphatic system disorders | 12/611 | 39/305 |
| DiarrhoeaGastrointestinal disorders | 77/611 | 31/305 |
| HeadacheNervous system disorders | 66/611 | 26/305 |
ITT Population included all randomized/enrolled participants.
| Age, Categorical(Participants) | Roxadustat | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 271 | 146 | 417 |
| >=65 years | 345 | 160 | 505 |
| Sex: Female, Male(Participants) | Roxadustat | Placebo | Total |
|---|---|---|---|
| Female | 375 | 176 | 551 |
| Male | 241 | 130 | 371 |
| Ethnicity (NIH/OMB)(Participants) | Roxadustat | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 165 | 84 | 249 |
| Not Hispanic or Latino | 451 | 222 | 673 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Roxadustat | Placebo | Total |
|---|---|---|---|
| American Indian/ Alaskan Native | 6 | 1 | 7 |
| Asian | 310 | 151 | 461 |
| Black/African American | 76 | 28 | 104 |
| Native Hawaiian or Other Pacific Islander | 2 | 4 | 6 |
| White | 176 | 99 | 275 |
| Other | 46 | 23 | 69 |
Showing the first 100 of 145 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Nov 2012 to primary completion in Sep 2018, 70 months.
Results were first posted in Oct 2021, 3 years after primary completion. A results delay was requested in Oct 2019.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 70 months is above that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat